The DOI matches its Crossref record.
Efficacy and Cost Effectiveness of Adjuvant Chemotherapy in Women with Node-Negative Breast Cancer: A Decision-Analysis Model
Open accessAbstract
BACKGROUND: In 1988 the National Cancer Institute issued a Clinical Alert that has been widely interpreted as recommending that all women with node-negative breast cancer receive adjuvant chemotherapy. Acceptance of this recommendation is controversial, since many women who would not have a recurrence would be treated. METHODS: Using a decision-analysis model, we studied the cost effectiveness of chemotherapy in cohorts of 45-year-old and 60-year-old women with node-negative breast cancer by calculating life expectancy as adjusted for quality of life. The analysis evaluated different scenarios of the benefit of therapy: improved disease-free survival for five years, with a lesser effect on overall survival (base line); a lifelong benefit from chemotherapy; and a benefit in disease-free survival with no change in overall survival by year 10. The base-line analysis assumed a 30 percent reduction in the relative risk of recurrence for five years after treatment. RESULTS: For the 45-year-old woman, the base-line analysis found an average lifetime benefit from chemotherapy of 5.1 quality-months at a cost of $15,400 per quality-year. The 60-year-old women gained 4.0 quality-months at a cost of $18,800 per quality-year. Under the more and less optimistic scenarios, the benefit of chemotherapy varied from 1.4 to 14.0 quality-months for both groups. CONCLUSIONS: Chemotherapy substantially increases the quality-adjusted life expectancy of an average woman at a cost comparable to that of other widely accepted therapies. This benefit decreases markedly if the changes in long-term survival are less than in disease-free survival. Given its uncertain duration, the benefit may be too small for many women to choose chemotherapy. Selective use of chemotherapy to maximize the benefit to individual patients may be possible with refinements in risk stratification and explicit assessment of the patients' risk preferences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
One Thousand Health-Related Quality-of-Life Estimates
Tengs, T. O., & Wallace, A. (2000) · Medical Care · doi:10.1097/00005650-200006000-00004 · Cited by 662
KLIJN, J. G. M., BERNS, P. M. J. J., SCHMITZ, P. I. M., & FOEKENS, J. A. (1992) · Endocrine Reviews · doi:10.1210/edrv-13-1-3 · Cited by 597
The effects of chronic medical conditions on work loss and work cutback
Kessler, R. C., Greenberg, P. E., Mickelson, K. D., Meneades, L. M., & Wang, P. S. (2001) · Journal of Occupational and Environmental Medicine · doi:10.1097/00043764-200103000-00009 · Cited by 468
Accounting for future costs in medical cost-effectiveness analysis
Meltzer, D. (1997) · Journal of Health Economics · doi:10.1016/s0167-6296(96)00507-3 · Cited by 444
Schrag, D., Kuntz, K. M., Garber, J. E., & Weeks, J. C. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362022 · Cited by 435
Metadata
- Authors
- Hillner, B. E., & Smith, T. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1991-01-17
- Volume
- 324
- Issue
- 3
- Pages
- 160-168
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2083224152
- Cited by
- 237
- References
- 0
- FWCI
- 66.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Cost Effectiveness of Adjuvant Chemotherapy in Women with Node-Negative Breast Cancer: A Decision-Analysis Model. https://app.cochat.ai/papers/10.1056/nejm199101173240305
- The paper
- Hillner, B. E., & Smith, T. J. (1991). Efficacy and Cost Effectiveness of Adjuvant Chemotherapy in Women with Node-Negative Breast Cancer: A Decision-Analysis Model. New England Journal of Medicine. https://doi.org/10.1056/nejm199101173240305
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.